AACR Annual Meeting | Conference

Dr. Moyers on Real-World Data With Adjuvant Immunotherapy in Melanoma

June 24th 2020

Justin Moyers, MD, discusses real-world data and sociodemographic factors from an early analysis of the National Cancer Database associated with the treatment of adjuvant immunotherapy in stage III melanoma.

Double PIK3CA Mutations in Breast Cancer Increase Sensitivity to PI3Kα Inhibition

June 24th 2020

Patients with breast cancer who harbor multiple PIK3A-mutant tumors achieved a higher clinical benefit from PI3Kα inhibition compared with single mutant tumors according to response analysis data from the SANDPIPER trial.

Neoadjuvant Nivolumab/Ipilimumab Improves RFS in Stage III Macroscopic Melanoma

June 24th 2020

The neoadjuvant combination of nivolumab and ipilimumab continues to demonstrate a benefit in RFS compared with the combination given in the adjuvant setting in patients with stage III macroscopic melanoma.

Dr. Figel on Preclinical Research With Survivin Isoforms in Cancer Cells

June 24th 2020

Sheila Figel, PhD, a neuro-oncologic scientist with Roswell Park Comprehensive Cancer Center, discusses preclinical research with canonical and noncanonical that are displayed on the surface of cancer cells.

Nivolumab/Ipilimumab Demonstrates OS Benefit in Advanced NSCLC With Brain Metastases

June 24th 2020

The combination of nivolumab and ipilimumab provided similar clinical benefit to that of chemotherapy when given as a frontline treatment for patients with advanced non–small cell lung cancer who had stable and treated brain metastases at baseline.

Tiragolumab/Atezolizumab Shows Early First-in-Human Efficacy in Frontline PD-L1+ NSCLC

June 24th 2020

Tiragolumab in combination with atezolizumab (Tecentriq) demonstrated early clinical activity and was found to be well tolerated in patients with advanced solid tumors, including those with metastatic non–small cell lung cancer who were PD-L1 positive and had not received prior checkpoint inhibition.

Dr. Horn on Updated IMpower133 Data in Small Cell Lung Cancer

June 23rd 2020

Leora Horn, MD, MSc, discusses data from an updated analysis of the phase 3 IMpower133 trial, which examined the first-line combination of atezolizumab (Tecentriq), carboplatin, and etoposide in small cell lung cancer.

Tucatinib Produces Potent Preclinical Antitumor Activity, CNS Penetrance in HER2+ Breast Cancer

June 23rd 2020

The HER2-selective TKI tucatinib (Tukysa) demonstrated potent antitumor activity alone and in combination with ado-trastuzumab emtansine (T-DM1; Kadcyla) in HER2-overexpressing breast cancer cell lines and xenograft models.

SM-88 Shows Promising Preclinical Antitumor Activity Across Several Cancers

June 23rd 2020

The oral modified dysfunctional tyrosine SM-88 has demonstrated antitumor activity and appears to broadly effect the immune dynamics of the tumor microenvironment, according to early data from 2 xenograft studies.

ctDNA Clearance Shows Correlation With PFS Improvement in EGFR+/MET+ NSCLC

June 23rd 2020

Circulating tumor DNA clearance of EGFR mutation may be predictive of prolonged progression-free survival for patients with EGFR-mutant, MET-amplified non–small cell lung cancer with detectable ctDNA at baseline.

x